proxyvotesnow.com

Home › Companies › Voyager Therapeutics, Inc. › 2025-2026

Voyager Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Voyager Therapeutics, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 7Reported items
  • 146Asset managers
  • 930Fund votes
  • 2026-06-09Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Voyager Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Voyager Therapeutics, Inc.

These tallies are Voyager Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Voyager Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-09
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: James A. Geraghty 23,336,364---- 9,772,13313,057,844 Majority: yes
Elect Director: Steven Hyman, M.D. 30,442,488---- 2,666,00913,057,844 Majority: yes
Elect Director: Alfred Sandrock, M.D., Ph.D. 31,890,428---- 1,218,06913,057,844 Majority: yes
Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers. 32,041,373910,087157,037 --13,057,844 Passed
Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2026. 45,902,883108,561154,897 ---- Passed
Voyager's stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 43,464,4912,593,426108,424 ---- Passed

Source: Voyager Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.

How asset managers voted at the Voyager Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 146 asset managers that disclosed a Voyager Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Voyager Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 7 wordings of this item as funds reported it.

97% Passed · of votes cast

FOR 97%
FOR: 32,041,373AGAINST: 910,087

Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders approved a non-binding, advisory proposal regarding the compensation of Voyager's named executive officers.”): 32,041,373 for, 910,087 against — passed, per its Form 8-K filed 2026-06-10 (Item 5.07). Of all 60,421,287 outstanding shares: 53.0% for, 2% against (54.5% of the company cast a for/against vote).

The 144 asset managers below cast 97% of the shares they voted on this item FOR (19,913,798 for, 573,675 against).

FOR 97%
FOR: 19,913,798 (97.2%)AGAINST: 573,675 (2.8%)ABSTAIN: 1,115 (0.0%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,320,621922 00For
Vanguard3,294,5142 10For
Vestal Point Capital, LP2,179,0040 00For
Fidelity1,245,6860 00For
Erste Asset Management GmbH1,095,1410 00For
GEODE CAPITAL MANAGEMENT, LLC1,085,1180 00For
State Street853,9611,853 00For
Two Sigma454,8400 00For
Dimensional400,5880 00For
ARMISTICE CAPITAL, LLC394,1460 00For
T. Rowe Price354,3830 00For
Renaissance346,3320 00For
FIDUCIARY TRUST CO334,3970 00For
American Century0294,164 00Against
ACADIAN ASSET MANAGEMENT LLC272,2170 00For
Charles Schwab250,2220 00For
Northern Trust223,5740 00For
Point72216,7320 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC199,5050 00For
Hudson Bay Capital Management LP181,2500 00For
Bridge Builder Trust177,6450 00For
Goldman Sachs174,5590 00For
MELLON INVESTMENTS Corp151,0710 00For
Nuveen118,5220 00For
Citadel113,9130 00For

Showing the 25 largest of 144 asset managers. See all 144 in the interactive database.

2. To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: Alfred Sandrock M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 31,890,428WITHHELD: 1,218,069

Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: Alfred Sandrock, M.D., Ph.D.”): 31,890,428 for, 1,218,069 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,421,287 outstanding shares: 52.8% for, 2% withheld (54.8% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (8,992,655 for, 0 against).

FOR 97%
FOR: 8,992,655 (96.8%)ABSTAIN: 298,757 (3.2%)
Largest asset managers voting on “To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stock” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,975,0510 40For
BlackRock2,492,7520 00For
Erste Asset Management GmbH1,095,1410 00For
Fidelity1,085,9830 00For
Dimensional00 276,5490Abstain
Bridge Builder Trust177,6450 00For
American Century146,5170 00For
Charles Schwab125,1090 00For
Equitable113,8940 00For
TIAA92,7130 00For
MASTER INVESTMENT PORTFOLIO88,3280 00For
BRIDGEWAY FUNDS INC81,2590 00For
Goldman Sachs79,6680 00For
QUANTITATIVE MASTER SERIES LLC76,5990 00For
Allspring45,1150 00For
T. Rowe Price40,7930 00For
Lincoln Financial34,1000 5,2370For
Northern Trust31,8590 00For
AIG/SunAmerica24,7940 00For
Global X22,3370 00For
Nationwide19,1080 00For
State Street18,5640 00For
Innovator ETFs Trust16,5660 00For
Pacific Life16,4740 00For
Brighthouse15,3880 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

3. To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: James A. Geraghty

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD 30%
FOR: 23,336,364WITHHELD: 9,772,133

Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: James A. Geraghty”): 23,336,364 for, 9,772,133 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,421,287 outstanding shares: 39% for, 16% withheld (54.8% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (7,244,869 for, 0 against).

FOR 78%ABSTAIN 22%
FOR: 7,244,869 (78.0%)ABSTAIN: 2,046,543 (22.0%)
Largest asset managers voting on “To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stock” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,969,5100 5,5450For
BlackRock2,492,7520 00For
Erste Asset Management GmbH00 1,095,1410Abstain
Fidelity1,084,7830 1,2000For
Dimensional00 276,5490Abstain
Bridge Builder Trust20,5590 157,0860Abstain
American Century00 146,5170Abstain
Charles Schwab125,1090 00For
Equitable83,5840 30,3100For
TIAA92,7130 00For
MASTER INVESTMENT PORTFOLIO88,3280 00For
BRIDGEWAY FUNDS INC00 81,2590Abstain
Goldman Sachs79,6680 00For
QUANTITATIVE MASTER SERIES LLC76,5990 00For
Allspring00 45,1150Abstain
T. Rowe Price40,7930 00For
Lincoln Financial00 39,3370Abstain
Northern Trust00 31,8590Abstain
AIG/SunAmerica00 24,7940Abstain
Global X22,3370 00For
Nationwide19,1080 00For
State Street00 18,5640Abstain
Innovator ETFs Trust16,5660 00For
Pacific Life16,4740 00For
Brighthouse00 15,3880Abstain

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

4. To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal: Steven Hyman, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 30,442,488WITHHELD: 2,666,009

Voyager Therapeutics, Inc.’s own tally for this item (“Elect Director: Steven Hyman, M.D.”): 30,442,488 for, 2,666,009 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,421,287 outstanding shares: 50.4% for, 4% withheld (54.8% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (8,958,616 for, 0 against).

FOR 96%
FOR: 8,958,616 (96.4%)ABSTAIN: 332,795 (3.6%)
Largest asset managers voting on “To elect each of the following nominees to serve as a Class II director until the 2029 annual meeting of stock” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,971,3220 3,7320For
BlackRock2,492,7520 00For
Erste Asset Management GmbH1,095,1410 00For
Fidelity1,085,9830 00For
Dimensional00 276,5490Abstain
Bridge Builder Trust177,6450 00For
American Century146,5170 00For
Charles Schwab125,1090 00For
Equitable83,5840 30,3100For
TIAA92,7130 00For
MASTER INVESTMENT PORTFOLIO88,3280 00For
BRIDGEWAY FUNDS INC81,2590 00For
Goldman Sachs79,6680 00For
QUANTITATIVE MASTER SERIES LLC76,5990 00For
Allspring45,1150 00For
T. Rowe Price40,7930 00For
Lincoln Financial34,1000 5,2370For
Northern Trust31,8590 00For
AIG/SunAmerica24,7940 00For
Global X22,3370 00For
Nationwide19,1080 00For
State Street18,5640 00For
Innovator ETFs Trust16,5660 00For
Pacific Life16,4740 00For
Brighthouse15,3880 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares of common stock.

CAPITAL STRUCTURECompany result: Passed

Combines 2 wordings of this item as funds reported it.

94% Passed · of votes cast

FOR 94%
FOR: 43,464,491AGAINST: 2,593,426

Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 12”): 43,464,491 for, 2,593,426 against — passed, per its Form 8-K filed 2026-06-10 (Item 5.07). Of all 60,421,287 outstanding shares: 72% for, 4% against (76% of the company cast a for/against vote).

The 45 asset managers below cast 99.9% of the shares they voted on this item FOR (9,291,408 for, 4 against).

FOR 99.9%
FOR: 9,291,408 (100.0%)AGAINST: 4 (0.0%)
Largest asset managers voting on “To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,975,0514 00For
BlackRock2,492,7520 00For
Erste Asset Management GmbH1,095,1410 00For
Fidelity1,085,9830 00For
Dimensional276,5490 00For
Bridge Builder Trust177,6450 00For
American Century146,5170 00For
Charles Schwab125,1090 00For
Equitable113,8940 00For
TIAA92,7130 00For
MASTER INVESTMENT PORTFOLIO88,3280 00For
BRIDGEWAY FUNDS INC81,2590 00For
Goldman Sachs79,6680 00For
QUANTITATIVE MASTER SERIES LLC76,5990 00For
Allspring45,1150 00For
T. Rowe Price40,7930 00For
Lincoln Financial39,3370 00For
Northern Trust31,8590 00For
AIG/SunAmerica24,7940 00For
Global X22,3370 00For
Nationwide19,1080 00For
State Street18,5640 00For
Innovator ETFs Trust16,5660 00For
Pacific Life16,4740 00For
Brighthouse15,3880 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDCompany result: Passed

Combines 2 wordings of this item as funds reported it.

99.7% Passed · of votes cast

FOR 99.7%
FOR: 45,902,883AGAINST: 108,561

Voyager Therapeutics, Inc.’s own tally for this item (“Voyager's stockholders ratified the appointment of Ernst & Young LLP as Voyager's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 45,902,883 for, 108,561 against — passed, per its Form 8-K filed 2026-06-10 (Item 5.07). Of all 60,421,287 outstanding shares: 76% for, 0.2% against (76% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (9,291,412 for, 0 against).

FOR 100%
FOR: 9,291,412 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at Voyager Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,975,0550 00For
BlackRock2,492,7520 00For
Erste Asset Management GmbH1,095,1410 00For
Fidelity1,085,9830 00For
Dimensional276,5490 00For
Bridge Builder Trust177,6450 00For
American Century146,5170 00For
Charles Schwab125,1090 00For
Equitable113,8940 00For
TIAA92,7130 00For
MASTER INVESTMENT PORTFOLIO88,3280 00For
BRIDGEWAY FUNDS INC81,2590 00For
Goldman Sachs79,6680 00For
QUANTITATIVE MASTER SERIES LLC76,5990 00For
Allspring45,1150 00For
T. Rowe Price40,7930 00For
Lincoln Financial39,3370 00For
Northern Trust31,8590 00For
AIG/SunAmerica24,7940 00For
Global X22,3370 00For
Nationwide19,1080 00For
State Street18,5640 00For
Innovator ETFs Trust16,5660 00For
Pacific Life16,4740 00For
Brighthouse15,3880 00For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Showing the 6 reported items with the widest manager coverage, of 7 in total. View every item.

Largest Voyager Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Voyager Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,421,287 shares outstanding at the time of that meeting.

Top Voyager Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 7.15%
2Vanguard 5.45%
3Vestal Point Capital, LP 3.61%
4Fidelity 2.06%
5Erste Asset Management GmbH 1.81%
6GEODE CAPITAL MANAGEMENT, LLC 1.80%
7State Street 1.42%
8Two Sigma 0.75%
9Dimensional 0.66%
10ARMISTICE CAPITAL, LLC 0.65%

Reported Voyager Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Voyager Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 9.22% 13F
Integrated Core Strategies (US) LLC 7.34% 13G
Millennium Management 5.67% 13F
Vanguard Group 5.41% 13F
Geode Capital 1.74% 13F
State Street 1.57% 13F
Dimensional Fund Advisors 1.45% 13F
Two Sigma 1.02% 13F
Renaissance Technologies 0.96% 13F
Morgan Stanley 0.90% 13F

Percentages above are of 60,421,287 shares outstanding, as reported by Voyager Therapeutics, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Voyager Therapeutics, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Voyager Therapeutics, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 146 asset managers reported how they voted in their SEC Form N-PX filings, covering 930 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the proposal passed with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Voyager Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-10.

Voyager Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).